Benmelstobart Plus Anlotinib Versus Sunitinib as First-Line Treatment for Advanced Non-Clear Cell Renal Cell Carcinoma (clinicaltrials.gov) - Oct 21, 2026 - P3 | N=126 | Active, not recruiting | Sponsor: Sun Yat-sen University
New P3 trial • Genito-urinary Cancer • Non Clear Cell Renal Cell Carcinoma • Oncology • Solid Tumor • PD-L1
|